The Korean Pharmaceutical Association (KPA) strongly objected to the withdrawal of step-by-step abolition policy for generic co-biological equivalence testing.

On the 28th, the Korean Pharmaceutical Association (Chairman Dae-up Kim) announced that the Regulatory Reform Committee recommended the withdrawal of the amendment to the 'Regulation for Pharmaceutical Approvals, Notifications and Reviews', which contains the phased abolition of the generic bioequivalence test, and the MFDS, which accepted this without policy alternatives, is pursuing lush policy.

The KPA said, "Even if there are three or four alternative generics available in the pharmacy, the patients will have to experience the